Accord Expands CNS Ambitions With Zubsolv Deal

Sets Launch Date For Opioid-Dependence Treatment In First Of 29 Markets

 
• By Dave Wallace

Accord Healthcare has struck a European licensing deal with Orexo for its Zubsolv opioid-dependence treatment, building on a CNS business that also includes a recent distribution agreement with Molteni Farmaceutici for Sixmo.

CNS Pills Bottle
The deal builds on Accord’s agreement with Molteni for Sixmo • Source: Shutterstock

More from Deals

More from Business